IceCure Medical (NASDAQ:ICCM) Earns Buy Rating from HC Wainwright

IceCure Medical (NASDAQ:ICCM)‘s stock had its “buy” rating reiterated by HC Wainwright in a research note issued to investors on Friday,Benzinga reports. They currently have a $2.50 target price on the stock. HC Wainwright’s price target points to a potential upside of 125.23% from the company’s current price.

IceCure Medical Price Performance

NASDAQ:ICCM opened at $1.11 on Friday. IceCure Medical has a 12-month low of $0.48 and a 12-month high of $1.66. The firm has a market capitalization of $61.61 million, a price-to-earnings ratio of -3.83 and a beta of 0.37. The stock’s 50 day moving average price is $1.32 and its two-hundred day moving average price is $0.99. The company has a quick ratio of 2.27, a current ratio of 2.67 and a debt-to-equity ratio of 0.02.

IceCure Medical (NASDAQ:ICCM) last announced its quarterly earnings results on Thursday, March 27th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.01). IceCure Medical had a negative net margin of 376.85% and a negative return on equity of 124.44%. The business had revenue of $1.07 million for the quarter, compared to analyst estimates of $1.07 million. On average, analysts anticipate that IceCure Medical will post -0.28 earnings per share for the current year.

Institutional Trading of IceCure Medical

A hedge fund recently raised its stake in IceCure Medical stock. XTX Topco Ltd grew its holdings in IceCure Medical Ltd (NASDAQ:ICCM) by 123.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 58,866 shares of the company’s stock after acquiring an additional 32,555 shares during the quarter. XTX Topco Ltd owned 0.11% of IceCure Medical worth $65,000 as of its most recent SEC filing. Institutional investors own 0.62% of the company’s stock.

IceCure Medical Company Profile

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.